|Home | About | Journals | Submit | Contact Us | Français|
Glycemic control with intensive insulin therapy (IIT) has received widespread adoption secondary to findings of improved clinical outcomes and survival in the burn population. Severe burn as a model for trauma is characterized by a hypermetabolic state, hyperglycemia, and insulin resistance. In this article, we review the findings of a burn center research facility in terms of understanding glucose management. The conferred benefits from IIT, our findings of poor outcomes associated with glycemic variability, advantages from preserved diurnal variation of glucose and insulin, and impacts of glucometer error and hematocrit correction factor are discussed. We conclude with direction for further study and the need for a reliable continuous glucose monitoring system. Such efforts will further the endeavor for achieving adequate glycemic control in order to assess the efficacy of target ranges and use of IIT.
Widespread adoption of intensive insulin therapy (IIT) resulted from promising reports1–8 that tight glycemic control improves outcomes in critically ill patients. Despite findings9,10 that IIT in tight normal range (80 to 110 mg/dl) confers no benefit to most intensive care unit (ICU) patients and, in fact, increases risk of hypoglycemic events,2,10–14 the practice of moderate glycemic control (140 to 180 mg/dl) continues to be advocated.15,16 Unfortunately, consensus on population-specific target ranges is lacking.
Clinical practices guiding the treatment of the trauma population may be the cornerstone for management of the critically ill, but patients with major burns epitomize the hyperdynamic physiologic stress response.17,18 Burn trauma differs in severity and duration as compared to that of other critically ill patients.18 The exaggerated stress response following burn injury is characterized by alterations in endocrinologic and immunologic function,17,18 glucose intolerance or insulin resistance,19,20 negative nitrogen balance, catabolism, and an overall hyper-metabolic state.21,22 These patients have reliably long lengths of hospital stay, more complications, frequent septic events, and increased mortality compared to general ICU patients.
Although debate continues about the ideal glucose target range for optimal benefit, the current burn community practice is to achieve relatively tight control, with 73% of verified American Burn Association (ABA) centers reporting target glucose of less than 120 mg/dl in a survey.23 Furthermore, studies support glycemic control for improved skin graft survival,24 reduction of infection,25 and improved survival26 in the severely burned patient. In the large international study Normoglycaemia in Intensive Care Evaluation and Survival Using Glucose Algorithm Regulation (NICE-SUGAR, trauma patients did in fact demonstrate the most benefit from IIT from the observed trend toward improved survival (p = .07).9 Undoubtedly, injured patients differ from other critically ill patients. Thermal injuries represent an extreme model of trauma with prolonged recovery time, supporting the notion that IIT confers benefit to the burn population as well. Therefore, it is difficult to ascertain the effect of the NICE-SUGAR study on practice within the burn community. Certainly, prospective multicenter trials are critical to determining the ideal target glucose ranges to optimize burn management.
The purpose of this review is to describe the recent advances in our understanding of glucose management for the burned patient, specifically examining the effects of glycemic variability on outcome, diurnal rhythms of insulin and glucose, point-of-care (POC) glucometer error, and development of an artificial pancreas to optimize glucose control in the critically ill.
Severe burn injury [greater than 40% of the total body surface area (TBSA)] is a devastating form of trauma that ultimately affects all metabolic processes. Underlying metabolism is accelerated, basal temperature is elevated, tachycardia persists, and stress hormones are released.27,28 Nutritional demands are dramatically increased, up to twice the normal requirements of traditional ICU patients.27 Because burn patients develop hepatic dysfunction and fail to appropriately metabolize lipids,27 enteral feeding formulas at our center are low in lipids (16%) and high in carbohydrates (63%) and proteins (21%).
Recent advances in the surgical management of burn wounds advocate total excision of all nonviable tissue and covering with autogolous, cadaver, or temporary biologic grafts.29 New wounds are created during harvest for donor grafts, further increasing nutritional requirements for wound healing. Serial surgical procedures are required to continue the process of wound closure, repeatedly inciting the stress response and prolonging the hypermetabolic state. Enteral feeds are frequently discontinued for surgery, delayed gastric emptying, vasoactive agent-dependent septic shock, and daily showers required for wound care. Hyperglycemia is common because of the stress of frequent interventions, sepsis, and high-volume carbohydrate feeds. Insulin resistance, elevated production of counter-regulatory hormones, and administration of exogenous corticosteroids for adrenal insufficiency further exacerbate glycemic imbalance. Importantly, there is a greater risk of clinically significant hypoglycemic events (<40 mg/dl) for burn patients. Significant loss of muscle mass due to catabolism, hepatic dysfunction, endocrine and hormonal derangement, frequent interruption of enteral feeds, and significant procedural metabolic stress amplify the frequency of hypoglycemic episodes. Combined, these factors contribute to the difficulty of maintaining euglycemia in the critically ill burn patient.
Great debate surrounds current IIT practices, with disparate outcomes reported for various critical care populations. Surgical patients appear to benefit from tight control,4,8 yet medical ICU patients do not respond as favorably unless ICU stay is greater than 3 days.7 Meta-analysis of published reports reveals no improvement in overall outcomes for IIT practices,10 although some benefit may occur for surgical patients.2,30 However, trauma and burn patients have been shown to have high morbidity and mortality associated with hyperglycemia, supporting the practice of tight glycemic control for these patients.1,6,31,32 The NICE-SUGAR9 study reported a significant increase in 90-day mortality for ICU patients receiving IIT targeting glucose levels of 81–108 mg/dl compared to a conservative target of less than 180 mg/dl. Conversely, the only subgroups in this study that apparently benefited from IIT were the trauma population and patients requiring exogenous corticosteroid administration. As previously noted, severe burn is considered a representative model of injury, and thus the findings of the NICE-SUGAR study9 support IIT practice for burn and trauma populations. The benefit of glycemic control with exogenous insulin infusion for the burn patient may be linked to the reduction of infectious complications25,26,33 and multiorgan failure.34 Insulin therapy is associated with the attenuation of the hypermetabolic state,35,36 improvement in wound healing,37 and preservation of muscle mass,38,39 factors essential to the survival of patients with extensive burn injuries. In our burn center, we reviewed the chart of all adult patients with >20% TBSA burns treated with insulin infusions between 2002 and 2004. During the first 7 days of admission, patients who manifested better glucose control (n = 47, mean glucose 133 mg/dl) had a 45% reduction in mortality compared to patients in whom tight control was not obtained (n = 41, mean glucose 174 mg/dl). These findings have strengthened the resolve within our burn center to continue tight glycemic control for our ICU patients9 as we conduct further analysis to determine the ideal target range to maximize outcomes while minimizing exposure to hypoglycemic events.
Not only has hyperglycemia been shown to correlate with increased mortality in critically ill patients, but variability in glucose has also been associated with poor outcomes. Several clinical studies have demonstrated an association of higher fluctuation in glucose levels and increased mortality in ICU patients.41–43 Within our burn center, we noted a similar pattern in adult burn patients with a TBSA greater than 20%. A review was conducted for patients admitted who had at least 100 recorded blood glucose (BG) measurements and had been treated with IIT.44 The purpose of this analysis was to describe the effect of glycemic variability on mortality, defined as being greater than 50% time out of the 80 to 110 mg/dl target range. The average of individual glucose measurements out of range was 50% ± 8% (range of 30% to 65%) for an average of 840 (range of 103 to 5314) values per patient. The percentage excursion for a high variability score was 56% (n = 26) compared to 46% for those with low variability (n = 23; p < .001). There was no difference in injury severity score, age, TBSA injured, or gender between groups. Despite similar days of ventilator support and hospital and ICU length of stay, the more variable group was noted to have over twice the mortality of the less variable group (50% versus 22%; p ≤ .05). The question remains whether glucose variability represents severity of illness or whether failure to control glucose results in a poor outcome in the burned ICU patient. We are currently evaluating a large database composed of multiple centers to begin to address this conundrum.
Many circadian patterns present in healthy individuals are lost during critical illness, such as those of cortisol and leptin;45 however, patterns of glucose and insulin have been noted to persist in general ICU patients.46 Research at our burn center was conducted to establish the presence or absence of diurnal patterns of glucose and insulin in the burn-injured patient. To this end, a review was conducted of patients receiving at least 7 days of IIT.47 Blood glucose values and insulin requirements were time-matched between patients hourly from time of admission. A frequency analysis of glucose values revealed a strong 24 h pattern present on day 2, with peaks in glucose occurring at 5 p.m. and troughs at 5 a.m. A paired t test between our data and a cosine wave reflecting 24 h periodicity revealed a correlation of 0.82 (Figure 1). However, when the correlation of survivors was compared to that of nonsurvivors, the cosine equation deteriorated, and the survivors demonstrated a better fit (r2 = 0.82) than patients who died (r2 = 0.50). Furthermore, the cosine amplitude of the nonsurvivor glucose curve was significantly less than that of the survivor curve (8.4 versus 16.5 mg/dl, p = .01), representing blunted variation in the diurnal pattern. In addition, patterns of exogenous insulin requirements revealed a peak at noon and a trough occurring at midnight, an offset of 5 from glucose patterns, reflecting the complex interplay of glucose metabolism and insulin sensitivity in the critically ill burned patient. Coupled with the diurnal pattern of insulin requirements in the burn ICU patient is the overall increase in insulin requirement during the first week of ICU stay despite constant glucose levels.47 A regression analysis of exogenous insulin requirements over time reveals a linear increase during the first 7 days of hospitalization (slope = 0.13, r2 = 0.57, p < .001). Such increases in insulin to maintain euglycemia represent a trend for increasing insulin resistance over time. This pattern challenges our presumption that routine ICU practices such as continuous feeding regimens and fixed glycemic target ranges are appropriate despite their failure to match underlying physiologic processes noted in the circadian rhythms present in the critically ill.
Concurrent with the extensive adoption of IIT following the compelling results of Van den Berghe and associates published in 2001,8 further practice changes occurred within the critical care community. In 1999, Hébert and colleagues48 demonstrated improved outcomes in certain patients managed with a restrictive blood transfusion strategy, targeting hemoglobin of 7 mg/dl compared to a traditional value of 10 mg/dl. These positive findings were confirmed for the burn population by Kwan and coworkers,49 and the recent ABA survey showed that 51% of verified centers transfuse patients to hemoglobin levels of 7 mg/dl.23 Thus adoption of restrictive transfusion within the burn community is common, coupled with prevalent use of IIT to maintain tight glycemic control.
Independently, these events may lack profound clinical impact, but when combined, a storm is created when POC glucometer technology is used. These useful bedside devices certainly expedite the frequent glucose quantification required for safe implementation of IIT. However, POC technology was designed and approved for diabetes patients at home, targeting glucose levels under 200 mg/dl, and were never intended for use in the critical care environment where high precision and accuracy are required to avoid complications. Clinical practice changes advocating IIT at the same time that restrictive transfusion practices were adopted exceeded the capability of current POC technology. The margin of error noted in POC glucometer package inserts of 20%50 exceeds the recommendation of the Food and Drug Administration to achieve no more than 15% error,51 posing serious clinical risk when narrow target ranges of 80 to 110 mg/dl are routinely used.23 Such inaccuracy fails to meet the call by the American Diabetes Association (ADA) to limit POC error to less than 5%,52 thus conferring significant hypoglycemic risk for patients undergoing IIT.
The problem with current single-channel POC glucometer technology resides with the use of whole-blood samples for glucose quantification, as these devices are programmed to assume a normal hematocrit (HCT) of 40% (Figure 2). Thus the internal calculation of BG assumes a constant displacement of plasma by red blood cells (RBCs) in the sample; however, an anemic sample contains fewer RBCs, so less displacement occurs and ratio concentration is erroneous. The denominator for HCT is fixed, resulting in systematic glucose overestimation for anemic samples and underestimation for polycythemic samples.53–55 When relatively normal hemoglobin targets (10 mg/dl) guide blood transfusion, a patient will likely have an HCT closer to normal (30%), and error may be attenuated. However, since permissive anemia strategies target an HCT closer to 20% (7 mg/dl), half of normal levels, significant overestimation of true glucose values results because of the increased amount of glucose available to the sensor; the bias is therefore toward undetected hypoglycemia.
This problem of POC error is pervasive. According to the ABA survey of burn centers, 95% of verified centers routinely implement single-channel glucometers for POC glucose quantification to guide IIT therapy.23 The individual practice changes of tight glycemic control and permissive anemia combined with POC use have significantly increased the risk for occult hypoglycemia within the burn community.56 Although the HCT effect on glucometer performance is well described,53,55,57–59 no practical solutions have been proposed for popular single-channel devices.
Recognition of the effect of low HCT on POC glucometers within our burn center was the result of careful analysis. We observed a systematic overestimation of POC glucose values compared to laboratory values during a clinical study of high-dose insulin therapy. Potential factors affecting glucometer performance, including heat, humidity, age of test strips, chemical substances, altitude, condition of sample, condition of glucometer, and operator experience, were evaluated and eliminated. Additionally, use of capillary blood has been associated with glucometer inaccuracy.60–63 Severely burned patients tend to have injuries to the upper extremities, making capillary finger sticks impractical and peripheral intravenous access problematic. Frequent bouts of septic shock, requirements for vasoactive agents, and persistent generalized edema further complicate the accuracy of capillary sampling. Thus only arterial or venous samples are used for glucose quantification in our burn ICU.
Next, we assessed the type of laboratory specimen tube as a potential source of the systematic error. We routinely utilized additive-free serum separator BD Vacutainer® tubes (BD, Franklin Lakes, NJ) for chemistry analysis, including glucose quantification. Because erythrocytes continue to consume glucose ex vivo, the serum separator evacuation tube is not ideal for preserving glucose because of the lack of chemical additives to halt component depletion. However, a gray-top Vacutainer tube contains sodium fluoride, which is specifically designed to preserve glucose-containing specimens. We processed matched whole-blood samples to determine whether the type of evacuation tube could account for the discrepancy in the glucose measurements. Although moderate degradation of glucose occurred in the additive-free specimens, the difference was slight in comparison to that observed.56 Discovery of this effect has prompted a change in our standard of care for laboratory glucose quantification; currently, the sodium fluoride additive evacuator tube is used for all glucose samples and serves as the reference standard.
Finally, we evaluated the patient's HCT level relative to the degree of error (Figure 3) and found a linear correlation between the degree of anemia and the percentage error in the POC measurements. Thus HCT was deemed the most significant source of glucometer error in our burn ICU population. We performed a regression analysis of prospectively collected samples from hemodynamically stable subjects in our institution's burn, trauma, surgical, and medical ICUs. We compared glucose quantification by the SureStep™ Flexx (LifeScan, Milpitas, CA) single-channel POC glucometer with specimens collected in sodium fluoride evacuation tubes processed by the laboratory serum analyzer (Vitros Fusion, Ortho Clinical Diagnostics, Rochester, NY). The result was an error rate similar to that previously noted, 19% ± 7% for an average HCT of 25%. Use of a derived mathematical correction formula approximated the serum glucose value, reducing the mean error to -0.02% ± 4.78% (r2 = 0.97). The correction formula was as follows:
where LN is the natural log and HCT is the most recent for a hemodynamically stable patient.64 Validation of this formula and evaluation of three widely used POC glucometers used by ABA-verified burn centers were conducted on additional matched whole-blood specimens. Error after mathematical correction on the new samples using the SureStep Flexx resulted in a nonsignificant difference in POC measures from laboratory analysis. Using the same methodology for the original mathematical model, we performed a regression analysis for the other single-channel glucometers on prospectively collected and matched samples to develop device-specific correction formulas. Clinically acceptable correction to fulfill the requirement for IIT accuracy in the ICU was achieved for all devices tested (Table 1).64 Furthermore, use of the mathematical formulas achieved correlation with the reference standard that meets the ADA-recommended 5% error rate.52
The question of when to apply the correction formulas was answered with a large retrospective review of 12,800 glucose and HCT-matched measurements to determine the point at which a clinically significant error occurred (Figure 3; U.S. Army Institute of Surgical Research unpublished data). The critical level at which an error greater than 5% occurred was 34% HCT. Researchers described significant anemia in general ICU patients with hemoglobin levels of less than 10 mg/dl within 3 days of ICU admission.65,66 Because of the risk of sepsis associated with blood transfusion,67,68 burn providers now maintain patients' hemoglobin levels below 10mg/dl.23,69 Maintaining hemoglobin of 7 mg/dl proposed by Hébert and colleagues48 targets a HCT of approximately 21%. Thus the problem of anemia is prevalent, and associated glucometer error due to HCT can affect all critically ill populations.
Fortunately, technological advances have now eliminated the problem of HCT effect.70 Evaluation of a new four-channel glucometer (StatStrip™, Nova Biomedical, Waltham, MA) conducted within our center has demonstrated reliable accuracy of this technology for general ICU patients with significant anemia.71 Prospectively collected whole-blood samples were tested on the single-channel SureStep Flexx, the four-channel StatStrip, and the central chemistry analyzer (Vitros Fusion), and tests for equivalence were performed. The average HCT for samples from the burn, trauma, surgical, and medical ICUs was 26.6% ± 5.2% (range of 18.5% to 43.1%). With a zone of indifference set for ±5%, the difference between the four-channel glucometer and the reference standard (laboratory analyzer) was -0.67% (95% confidence interval: -1.79% to 0.45%). There was no difference between the mathematically corrected single-channel and four-channel POC meters compared with the reference value (p = .61 and .65, respectively); however, the uncorrected single-channel glucometer was significantly different from the reference value (p = .006). Thus we concluded that HCT is the most significant factor associated with glucometer error, because our mathematical formula only incorporates HCT in correction, and the four-channel device corrects for numerous potentially interfering substances.71
The clinical importance of the effect of HCT on glucometer performance was revealed when we analyzed the rates of hypoglycemia before and after our burn unit instituted routine corrections for the effect of HCT. The hypo-glycemic rates were compared for all patients admitted to the burn center for the 6 months prior to implementation of correction and the 6 months after the change. We found a significant reduction in glucose values of less than 60 mg/dl and less than 80 mg/dl after adjustment. In addition, correction improved our time in the moderate glycemic range of 80 to 150 g/dl, but curiously, time in the tight glycemic range of 80 to 110 mg/dl was reduced (p = .002). When a comparison was made between the burn ICU where correction was implemented and the surgical ICU where use of uncorrected glucometer measurements continued, a significant reduction in hypo-glycemic events of less than 80 mg/dl was noted only in the burn unit (p < .001). This reduction is attributed to reduced insulin dosing for normal glucose values that were previously artificially inflated by the systematic glucometer error.
Correction factors for single-channel glucometers are device specific; we developed mathematical formulas for the four devices widely used at the time of our study by using blood from patients in the surgical, medical, and burn ICUs.23 Although the development of these formulas was based on serum blood samples, the results are applicable to capillary sampling when used with caution, given the inherent shortcomings of samples subject to poor perfusion.62,63 Mathematical correction64 always shifts the BG value lower than that calculated by the POC device, reducing potential insulin doses and thus erring on the side of safer dosing. Newer devices can be tested in anemic critically ill patients in the same manner64 for development of device-specific correction formulas when identified error exceeds ADA recommendations.72 Use of capillary samples is routine in general ICUs, and care must be taken to recognize patient-specific characteristics, such as hypoperfusion, edema, and use of vasoactive agents associated with systematic error.62 Aside from sampling source, no other uniform differences73 exist between burn and other ICU patients; thus mathematical correction of single-channel devices may be appropriate for all anemic patients. However, the highly accurate Nova StatStrip four-channel glucometer ushers in a new age of technology, setting new performance standards for POC devices.
Current methods to maintain euglycemia in the critically ill are immature at best. Future success for optimal glycemic control rests in our ability to replicate the capability of the human pancreas.74,75 Endocrine regulation in the body is dependent on varied responses to multiple sources of stimuli; a mechanical correlate is a nonlinear feedback control mechanism. Development of a responsive system to regulate infusion of exogenous insulin to control serum glucose levels has become an achievable goal with technological advances. Several components are required to create a virtual “closed-loop” system: a continuous insulin infusion pump, an intravascular continuous glucose monitoring (CGM) system, and a computer decision support software (CDSS) controller.76 Infusion pump technology is advanced, and such devices can network with software applications. Development of CGM technology74,77 is underway to provide real-time near-continuous BG quantification, minimizing a concomitant increase in nursing workload requirements.78 Several CDSS applications for insulin management are currently commercially available,79–82 demonstrating reduced glycemic excursion and significantly fewer hypoglycemic events.
Currently available CGM monitoring systems are sub-cutaneous sensors designed for use by diabetes outpatients. Goldberg and associates77 tested a commercially available device, Medtronic MiniMed™ (Northridge, CA), in a medical ICU. After a 72 h period, CGM glucose values were compared retrospectively to values obtained from a glucometer using capillary blood. Accuracy was similar to that of published outpatient studies, unaffected by edema, hypotension, or vasopressor therapy. While systematic differences were not found in the study, the accuracy of the CGM increased with elevated BG but was limited at hypoglycemic levels. Although the device readings are comparable to capillary BG values, it may fail to meet performance expectations for real-time use in an ICU setting using serum samples.
Critically ill patients, burn patients in particular, tend to be quite edematous with substantial soft tissue involvement and frequently require vasopressor support for low mean arterial pressure, compromising glucose equilibration between the intravascular and the interstitial compartments. Persistent edema present in the burned patient or physiologic delay of glucose equilibration between compartments due to low perfusion states will interfere with the ability to treat using real-time subcutaneous CGM sensors.
Further work has been done at our burn center to evaluate the ability of a CDSS system to successfully and safely guide IIT in the critically injured burn patient. A CDSS system was compared in a randomized crossover design to our standard of care paper-based insulin titration protocol. EndoTool™ (Hospira, Lake Forest, IL), a commercially available computer software package, was selected for the analysis. This program provides individualized hourly insulin infusion recommendations based on multiple control mathematics algorithms by means of the patient's glucose trend. Available for use at the bedside, this program allows the nurse to enter the hourly glucose value with any supplemental caloric intake into the system, and within seconds, the recommended insulin infusion rate is displayed with the suggested time for subsequent glucose quantification. Clinical judgment is paramount when managing IIT for critically ill patients, and nurses are at liberty to override computer recommendations based on the clinical scenario. However, we found that nurses accepted the computer recommendations more often than they followed the traditional paper protocol. Preliminary data demonstrate that computerized decision support provides better glycemic control in the 80 to 110 mg/dl target range without increased hypoglycemic events than our conventional nurse-managed paper protocol. As a result, the EndoTool computer software system has become the standard of care for glucose control in our burn ICU.
As an added benefit, computerized controllers have the potential to increase uniformity among clinical trials,83 improving consistency among individual providers. However, despite the enhancement in achieving the glycemic targets that CDSS confers over traditional paper protocols, routinely achieving the desired glucose range greater than 50% of the time remains problematic.83–86 Further improvements in CDSS technology are required for successful evaluation of the benefit of IIT and determination of ideal target ranges for unique critically ill populations.9
Additional investigation is underway to elucidate the pattern of insulin requirements and glucose levels in burn patients over the entire course of ICU management to determine differences between survivors and nonsurvivors. Additionally, no data exist comparing burned patients with and burned patients without diabetes or the effects of traumatic brain injury with regard to preservation of diurnal variability in glucose and insulin resistance patterns. Should differences be found related to diabetes status or concomitant traumatic brain injury, alteration of glycemic goals may be required to optimize care regimens.
Additional investigation is necessary to fully understand implications for the underlying diurnal variation in insulin resistance and glucose variability as related to feeding regimens and glucose targets in the ICU. Physiologic feeding such as bolus enteral feeds with nocturnal rest may more closely resemble natural rhythms and interrupt the trend for progressive insulin resistance over time associated with continuous enteral feeds. Furthermore, targeting more conservative glycemic goals during sleep, mimicking the natural diurnal pattern of glucose levels, may provide rest to cellular insulin receptors, again reducing the tendency of a progressively greater insulin requirement to maintain euglycemia during the ICU course. Implementation of computer decision support technology may facilitate such patient-specific therapies possessing the capability to target individual goals for glycemic control and cycle various glycemic ranges during a 24 h period. A reliable CGM system remains the barrier to emulating the basic function of the human pancreas. To that end, studies are underway to evaluate currently available Food and Drug Administration-cleared systems. Once a suitable device is validated, a large multicenter study is required to assess the effectiveness of the concept of the artificial pancreas in an open-loop model to initiate evaluation of IIT efficacy. However, understanding and ultimately manipulating the complex interplay of insulin sensitivity at the cellular level with dynamic hormonal fluctuation in the critically ill patient provides further challenges to optimizing glycemic control.
Although extensive research has focused on understanding the complex interplay of endocrine processes after burn injury to devise the optimum strategy for glucose regulation, many challenges and questions remain. Discovery of the effect of HCT on the accuracy and safety of widely used single-channel glucometers and, more importantly, development of an interim solution pending future technological advances in POC technology have the potential to improve the safety and clinical utility of these devices. Challenges related to sample source bias based on physiologic compromise must be addressed in future continuous monitoring technology, as use of capillary blood for POC glucose quantification for the patient in shock is unsuitable. Recognition of circadian rhythms in insulin and glucose regulation in the burn patient may alter traditional feeding practices and insulin targets. Finally, development of an artificial pancreas will benefit all critically ill patients with provision of optimal glycemic management. Until improvements are made to consistently reach and maintain patients within a target glucose range, the efficacy of IIT cannot be established.